Bozhi Hong Kong Biotech ETF (520690) rose as much as 1% intraday and was up 0.27% at 10:30 on July 24, while its benchmark Hang Seng Stock Connect Innovative Drug Select Index edged up 0.09%, according to Jiemian News. The ETF has gained 4.68% over the past two weeks through July 23, with turnover of 80.3444 million yuan and a 15.91% intraday turnover rate.
BeiGene said it will add $300 million to expand its flagship manufacturing base and clinical R&D center in Hopewell, west of Princeton, New Jersey, adding small-molecule drug production capacity. Separately, HLBIO said its independently developed EGFRxHER3 bispecific ADC, iza-bren, has enrolled its first patient in a phase III randomized trial for patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- breast cancer who failed endocrine therapy. Jiemian News also cited CICC's view that innovative drug stocks remain a low-valuation growth area outside AI themes, and said the index's latest price-to-book ratio is 3.28 times, below its level for more than 85.55% of the past year.
Beijing Launches Hong Kong Biotech ETF Up 0.27% as BeiGene Expands U.S. Site
2026-07-24 03:22:57
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
